ATRA Q3 2023 Earnings Call Summary | Stock Taper
Logo
Pricing Log In
ATRA

ATRA — Atara Biotherapeutics, Inc.

NASDAQ

Q3 2023 Earnings Call Summary

November 4, 2023

Summary of Atara Biotherapeutics Q3 2023 Earnings Call

1. Key Financial Results and Metrics

  • Atara reported cash reserves of approximately $102 million as of September 30, 2023.
  • The company anticipates a reduction in cash expenditures by about 40% (approximately $100 million) by the end of 2025 due to a strategic restructuring and an expanded partnership with Pierre Fabre.
  • Atara expects to extend its cash runway into Q3 2025.

2. Strategic Updates and Business Highlights

  • Atara announced an expanded global partnership with Pierre Fabre Laboratories for the commercialization of tab-cel (branded as Ebvallo in Europe), which includes:
    • Up to $640 million in additional consideration and significant double-digit tiered royalties on net sales.
    • An upfront payment of approximately $30 million and potential regulatory milestone payments of $100 million upon BLA approval.
    • Pierre Fabre will assume tab-cel's global development costs and manufacturing activities upon BLA approval.
  • The company is focused on advancing its pipeline, with key upcoming clinical milestones including:
    • EMBOLD study data readout for ATA188 expected in early November.
    • Initial data for the ATA3219 program in lymphoma anticipated in the second half of 2024.
  • Atara is also progressing with its CAR-T assets, specifically ATA3219 and ATA3431, targeting B-cell malignancies and autoimmune diseases.

3. Forward Guidance and Outlook

  • The company is optimistic about the potential of tab-cel, projecting U.S. peak sales of over $500 million, primarily from EBV+ PTLD indications.
  • Atara plans to disclose sufficient data from the EMBOLD study to allow investors to assess the potential value of ATA188.
  • The regulatory submission for tab-cel is expected in Q2 2024, with a comprehensive data package prepared for the BLA submission.

4. Bad News, Challenges, or Points of Concern

  • Atara is undergoing a strategic restructuring that will reduce its workforce by approximately 30%, which may impact morale and operational capacity in the short term.
  • The company faces significant competition in the biotech space, particularly in the development of therapies for progressive multiple sclerosis and CAR-T therapies.
  • There are inherent risks associated with clinical trials, including the potential for unfavorable EMBOLD study results, which could affect future development plans for ATA188.

5. Notable Q&A Insights

  • Management emphasized the importance of financial considerations in selecting Pierre Fabre as a partner, highlighting the need for a partner that could take over costs and activities associated with tab-cel.
  • The $500 million peak sales projection includes various indications, with a significant portion expected from the first indication (EBV+ PTLD).
  • The company is considering strategic partnerships for ATA188, particularly for Phase III trials, to retain value while leveraging external resources.
  • Management indicated that the EMBOLD trial data will include more than just primary endpoint results, potentially offering insights into longer-term outcomes and additional biomarkers.

Overall, Atara Biotherapeutics is positioned for growth through strategic partnerships and a focused pipeline, despite facing challenges related to restructuring and competitive pressures in the biotech industry.